Business
PepGen Announces Pricing of $100 Million Public Offering
BOSTON, September 25, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/148f1d6bbe866555040511fd9c77903e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7vF8mKDLVXy5ag2UoPiM3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/148f1d6bbe866555040511fd9c77903e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HCS7xGCTnrdolQh3qRZ9FA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/148f1d6bbe866555040511fd9c77903e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON, September 25, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. The offering is expected to close on or about September 26, 2025, subject to customary closing conditions. In addition, PepGen has granted the underwriters a 30-day option to purchase up to 4,687,500 additional shares of common stock at the public offering price, less the underwriting discount.","length":892,"tagName":"p"},{"type":"text","content":"Leerink Partners and Stifel are acting as joint bookrunning managers for the offering.","length":86,"tagName":"p"},{"type":"text","content":"PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.","length":259,"tagName":"p"},{"type":"text","content":"The securities are being offered pursuant to a registration statement on Form S-3 that was previously filed with, and subsequently declared effective on July 8, 2024, by the Securities and Exchange Commission ("SEC&qu...